Ham2Pose: Animating Sign Language Notation into Pose Sequences

Translating spoken languages into Sign languages is necessary for open communication between the hearing and hearing-impaired communities. To achieve this goal, we propose the first method for animating a text written in HamNoSys, a lexical Sign language notation, into signed pose sequences. As HamNoSys is universal, our proposed method offers a generic solution invariant to the target Sign language. Our method gradually generates pose predictions using transformer encoders that create meaningful representations of the text and poses while considering their spatial and temporal information. We use weak supervision for the training process and show that our method succeeds in learning from partial and inaccurate data. Additionally, we offer a new distance measurement for pose sequences, normalized Dynamic Time Warping (nDTW), based on DTW over normalized keypoints trajectories, and validate its correctness using AUTSL, a large-scale Sign language dataset. We show that it measures the distance between pose sequences more accurately than existing measurements and use it to assess the quality of our generated pose sequences. Code for the data pre-processing, the model, and the distance measurement is publicly released for future research

Random generation of finite and profinite groups and group enumeration

The following article appeared in Annals of Mathematics 173.2 (2011): 769-814 and may be found at http://annals.math.princeton.edu/2011/173-2/p04We obtain a surprisingly explicit formula for the number of random elements needed to generate a finite d-generator group with high probability. As a corollary we prove that if G is a d-generated linear group of dimension n then cd + log n random generators suffice. Changing perspective we investigate profinite groups F which can be generated by a bounded number of elements with positive probability. In response to a question of Shalev we characterize such groups in terms of certain finite quotients with a transparent structure. As a consequence we settle several problems of Lucchini, Lubotzky, Mann and Segal. As a byproduct of our techniques we obtain that the number of r-relator groups of order n is at most ncr as conjectured by Mann.The first author is supported in part by the Spanish Ministry of Science and Innovation, the grant MTM2008-06680. The second author is supported in part by OTKA grant numbers NK 72523 and NK 78439

Anti-RBD IgG antibodies and neutralizing antibody levels after the second BNT162b2 dose in patients with plasma cell disorders.

Patients with plasma cell disorders (PCD) are at an increased risk for severe morbidity and mortality due to COVID-19. Recent data have suggested that patients with hematological malignancies, including those with PCD, have suboptimal antibody response to COVID-19 vaccination. We compared the antibody titers of 213 patients with PCD to those of 213 immunocompetent healthcare workers after the second vaccine dose of the BNT162b2 mRNA vaccine. Blood samples were taken 2-4 weeks after the second vaccination and analyzed for anti-receptor binding-domain immunoglobulin G (RBD-IgG) antibodies and neutralizing antibodies (NA). At a median of 20 days after the second vaccine dose, 172 patients (80.8%) developed anti-RBD-IgG antibodies with a geometric mean titer (GMT) of 2.7 (95% confidence interval [CI], 2.4-3.1). In the control group 210 (98.9%) developed anti-RBD-IgG antibodies after a median of 21 days, with a GMT of 5.17 (95%CI, 4.8-5.6), p<0.0001. NA were observed in 151 patients with MM (70.9%) and in 210 controls (98.9%). The GMT of NA in patients with MM and controls was 84.4 (95% CI, 59.0-120.6), and 420.2 (95% CI, 341.4-517.1), respectively (p<0.0001). Multivariable logistic regression revealed that the number of prior therapy lines and age were significant predictors of poor humoral response among patients with MM. Injection site reaction, headache and fatigue were the most common adverse events after vaccination. Adverse events were less common in patients with MM than in controls. In conclusion, a significant percentage of patients with MM developed protecting NA to the BNT162b2 mRNA vaccine, which appears to be safe in this patient population